Tyvaso

NYHA class IV, NYHA Functional Class III Pulmonary arterial hypertension, refractory to conventional therapy + 4 more
Treatment
20 Active Studies for Tyvaso

What is Tyvaso

TreprostinilThe Generic name of this drug
Treatment SummaryTreprostinil is a medication that mimics prostacyclin, a natural chemical produced by the body. It is used to treat pulmonary hypertension, a type of high blood pressure in the lungs.
Remodulinis the brand name
Tyvaso Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Remodulin
Treprostinil
2002
47

Effectiveness

How Tyvaso Affects PatientsTreprostinil is a medicine used to relax the blood vessels in your lungs and body and stops platelets from sticking together. When taken, it can lower the pressure on your heart and increase the amount of blood it pumps out. Treprostinil can increase the chances of bleeding, and can cause low blood pressure or worsen the symptoms of pulmonary arterial hypertension. Taking treprostinil by inhalation may cause bronchospasms in people with asthma, COPD or bronchial hyperreactivity. When taken intravenously, it can cause complications and increase the risk of infection.
How Tyvaso works in the bodyTreprostinil is a medication used to treat pulmonary arterial hypertension. It works by widening your blood vessels and reducing the stickiness of platelets, which helps to lower your blood pressure. Treprostinil also helps to reduce inflammation in your body. To achieve this, it binds to and activates certain receptors in your cells, which leads to an increase in cAMP levels. This increase leads to the opening of potassium channels which eventually cause the blood vessels to widen.

When to interrupt dosage

The encouraged portion of Tyvaso is reliant upon the diagnosed ailment, including recalcitrant to standard therapy, Pulmonary Arterial Hypertension and NYHA class IV. The amount of dosage can be found in the table beneath, subject to the procedure of delivery (e.g. Solution or Inhalant).
Condition
Dosage
Administration
refractory to conventional therapy
1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.064 mg, 0.048 mg, 0.032 mg, 40.0 mg/mL, , 0.016 mg, 0.125 mg, 0.25 mg, 1.0 mg, 10.0 mg/mL, 2.0 mg/mL, 20.0 mg/mL, 5.0 mg, 2.5 mg, 1.74 mg/mL
Solution, Inhalant, Solution - Intravenous; Subcutaneous, , Kit; Tablet, extended release - Oral, Injection, solution, Oral, Kit; Tablet, extended release, Inhalant; Kit - Oral, Injection, Injection, solution - Intravenous; Subcutaneous, Inhalant - Respiratory (inhalation), Tablet, extended release - Oral, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Inhalant - Oral, Tablet, extended release, Inhalant; Kit, Respiratory (inhalation), Injection - Intravenous; Subcutaneous, Subcutaneous
NYHA class IV
1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.064 mg, 0.048 mg, 0.032 mg, 40.0 mg/mL, , 0.016 mg, 0.125 mg, 0.25 mg, 1.0 mg, 10.0 mg/mL, 2.0 mg/mL, 20.0 mg/mL, 5.0 mg, 2.5 mg, 1.74 mg/mL
Solution, Inhalant, Solution - Intravenous; Subcutaneous, , Kit; Tablet, extended release - Oral, Injection, solution, Oral, Kit; Tablet, extended release, Inhalant; Kit - Oral, Injection, Injection, solution - Intravenous; Subcutaneous, Inhalant - Respiratory (inhalation), Tablet, extended release - Oral, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Inhalant - Oral, Tablet, extended release, Inhalant; Kit, Respiratory (inhalation), Injection - Intravenous; Subcutaneous, Subcutaneous
NYHA Functional Class III Pulmonary arterial hypertension
1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.064 mg, 0.048 mg, 0.032 mg, 40.0 mg/mL, , 0.016 mg, 0.125 mg, 0.25 mg, 1.0 mg, 10.0 mg/mL, 2.0 mg/mL, 20.0 mg/mL, 5.0 mg, 2.5 mg, 1.74 mg/mL
Solution, Inhalant, Solution - Intravenous; Subcutaneous, , Kit; Tablet, extended release - Oral, Injection, solution, Oral, Kit; Tablet, extended release, Inhalant; Kit - Oral, Injection, Injection, solution - Intravenous; Subcutaneous, Inhalant - Respiratory (inhalation), Tablet, extended release - Oral, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Inhalant - Oral, Tablet, extended release, Inhalant; Kit, Respiratory (inhalation), Injection - Intravenous; Subcutaneous, Subcutaneous
WHO functional class II-III Pulmonary arterial hypertension
1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.064 mg, 0.048 mg, 0.032 mg, 40.0 mg/mL, , 0.016 mg, 0.125 mg, 0.25 mg, 1.0 mg, 10.0 mg/mL, 2.0 mg/mL, 20.0 mg/mL, 5.0 mg, 2.5 mg, 1.74 mg/mL
Solution, Inhalant, Solution - Intravenous; Subcutaneous, , Kit; Tablet, extended release - Oral, Injection, solution, Oral, Kit; Tablet, extended release, Inhalant; Kit - Oral, Injection, Injection, solution - Intravenous; Subcutaneous, Inhalant - Respiratory (inhalation), Tablet, extended release - Oral, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Inhalant - Oral, Tablet, extended release, Inhalant; Kit, Respiratory (inhalation), Injection - Intravenous; Subcutaneous, Subcutaneous
Pulmonary Arterial Hypertension
1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.064 mg, 0.048 mg, 0.032 mg, 40.0 mg/mL, , 0.016 mg, 0.125 mg, 0.25 mg, 1.0 mg, 10.0 mg/mL, 2.0 mg/mL, 20.0 mg/mL, 5.0 mg, 2.5 mg, 1.74 mg/mL
Solution, Inhalant, Solution - Intravenous; Subcutaneous, , Kit; Tablet, extended release - Oral, Injection, solution, Oral, Kit; Tablet, extended release, Inhalant; Kit - Oral, Injection, Injection, solution - Intravenous; Subcutaneous, Inhalant - Respiratory (inhalation), Tablet, extended release - Oral, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Inhalant - Oral, Tablet, extended release, Inhalant; Kit, Respiratory (inhalation), Injection - Intravenous; Subcutaneous, Subcutaneous
NYHA Functional Class III
1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.064 mg, 0.048 mg, 0.032 mg, 40.0 mg/mL, , 0.016 mg, 0.125 mg, 0.25 mg, 1.0 mg, 10.0 mg/mL, 2.0 mg/mL, 20.0 mg/mL, 5.0 mg, 2.5 mg, 1.74 mg/mL
Solution, Inhalant, Solution - Intravenous; Subcutaneous, , Kit; Tablet, extended release - Oral, Injection, solution, Oral, Kit; Tablet, extended release, Inhalant; Kit - Oral, Injection, Injection, solution - Intravenous; Subcutaneous, Inhalant - Respiratory (inhalation), Tablet, extended release - Oral, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Inhalant - Oral, Tablet, extended release, Inhalant; Kit, Respiratory (inhalation), Injection - Intravenous; Subcutaneous, Subcutaneous
Pulmonary Arterial Hypertension
1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.064 mg, 0.048 mg, 0.032 mg, 40.0 mg/mL, , 0.016 mg, 0.125 mg, 0.25 mg, 1.0 mg, 10.0 mg/mL, 2.0 mg/mL, 20.0 mg/mL, 5.0 mg, 2.5 mg, 1.74 mg/mL
Solution, Inhalant, Solution - Intravenous; Subcutaneous, , Kit; Tablet, extended release - Oral, Injection, solution, Oral, Kit; Tablet, extended release, Inhalant; Kit - Oral, Injection, Injection, solution - Intravenous; Subcutaneous, Inhalant - Respiratory (inhalation), Tablet, extended release - Oral, Injection, solution - Subcutaneous, Intravenous; Subcutaneous, Inhalant - Oral, Tablet, extended release, Inhalant; Kit, Respiratory (inhalation), Injection - Intravenous; Subcutaneous, Subcutaneous

Warnings

Tyvaso Contraindications
Condition
Risk Level
Notes
Severe Hepatic Impairment
Do Not Combine
There are 20 known major drug interactions with Tyvaso.
Common Tyvaso Drug Interactions
Drug Name
Risk Level
Description
Amifostine
Major
Treprostinil may increase the hypotensive activities of Amifostine.
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Treprostinil.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Treprostinil.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Treprostinil.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Treprostinil.
Tyvaso Toxicity & Overdose RiskTaking too much treprostinil may cause flushing, headache, nausea, vomiting, diarrhea, and low blood pressure. In some cases, patients may experience confusion or loss of consciousness. Studies have not shown any long-term effects on fertility or any increased risk of cancer or mutation.

Tyvaso Novel Uses: Which Conditions Have a Clinical Trial Featuring Tyvaso?

Currently, 54 active clinical trials are being conducted to examine the utility of Tyvaso in treating Pulmonary Arterial Hypertension, NYHA Functional Class III and Pulmonary Arterial Hypertension related conditions.
Condition
Clinical Trials
Trial Phases
Pulmonary Arterial Hypertension
52 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Phase 4, Early Phase 1
Pulmonary Arterial Hypertension
2 Actively Recruiting
Phase 1, Phase 4
NYHA Functional Class III
0 Actively Recruiting
refractory to conventional therapy
0 Actively Recruiting
NYHA class IV
0 Actively Recruiting
WHO functional class II-III Pulmonary arterial hypertension
0 Actively Recruiting
NYHA Functional Class III Pulmonary arterial hypertension
0 Actively Recruiting

Tyvaso Reviews: What are patients saying about Tyvaso?

5Patient Review
1/22/2013
Tyvaso for Pulmonary Arterial Hypertension
I just left my doctor's office and my blood pressure has already lowered significantly. I'm feeling much better and for the first time in years, I actually want to go outside and exercise. This is a miracle!
5Patient Review
3/26/2017
Tyvaso for Pulmonary Arterial Hypertension
I have Langerhans Cell Histiocytosis secondary to PAH and am currently on Adcirca, Letaris, Symbcort and Ventelin. Tyvaso has by far been the most effective at helping me breathe.
5Patient Review
5/25/2012
Tyvaso for Pulmonary Arterial Hypertension
I feel much better now that I'm using Tyvaso inhalation.
4Patient Review
7/22/2012
Tyvaso for Pulmonary Arterial Hypertension
I found that this medication helped me a lot, but only when I was also getting regular exercise. Otherwise, the side effects were pretty tough to deal with.
4Patient Review
9/30/2013
Tyvaso for Pulmonary Arterial Hypertension
I'm a 17 year old female and I've been using this drug for three years. I have noticed that it may have caused some anxiety and aggression issues. My breathing is good but I almost feel like I'm crashing when it's time for my next dosage. I also use Adcira and Letaris.

Patient Q&A Section about tyvaso

What is TYVASO used for?

"TYVASO Inhalation Solution and TYVASO DPI Inhalation Powder are prescription medicines used in adults to treat pulmonary arterial hypertension (PAH). TYVASO or TYVASO DPI can improve the ability to exercise." - Anonymous Online Contributor

Unverified Answer

What kind of drug is TYVASO?

"A prescription medicine called Tyvaso is used to treat symptoms of two conditions: pulmonary arterial hypertension and pulmonary arterial hypertension with interstitial lung disease. Tyvaso may be used alone or with other medications. It belongs to a class of drugs called prostacyclin analogs (PAH)." - Anonymous Online Contributor

Unverified Answer

How is TYVASO administered?

"You inhale TYVASO directly to your lungs during 4 short treatment sessions each day. Your doctor will work with you to reach your target maintenance dose, which is important so that you'll get the full benefit of your medicine." - Anonymous Online Contributor

Unverified Answer

How long does it take for TYVASO to work?

"†6MWD is the 6-Minute Walk Distance.

In a clinical study, people who added TYVASO to their background therapy for pulmonary arterial hypertension (PAH) walked an average of 22 meters farther in six minutes after 12 weeks of treatment, with some people seeing improvements as soon as six weeks after starting treatment." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Tyvaso

Have you considered Tyvaso clinical trials? We made a collection of clinical trials featuring Tyvaso, we think they might fit your search criteria.
Have you considered Tyvaso clinical trials? We made a collection of clinical trials featuring Tyvaso, we think they might fit your search criteria.
Have you considered Tyvaso clinical trials? We made a collection of clinical trials featuring Tyvaso, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top